A prospective, open-label, multicentre DACAB trial presented at the American Heart Association Scientific Sessions compared the efficacy and safety of a ticagrelor-aspirin combination with ticagrelor monotherapy and aspirin monotherapy on saphenous vein graft (SVG) patency administered within a day following coronary artery bypass grafting (CABG) for 12 months. The results showed that the SVG patency rate was highest in patients on aspirin plus ticagrelor followed by ticagrelor alone and aspirin alone (88.7%, 82.8%, 76.5%, respectively).